Opinion|Videos|August 8, 2024
Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL
Medical experts specializing in acute lymphoblastic leukemia explore emerging trends and potential future developments for CAR T-cell therapy in treating relapsed or refractory B-cell ALL.
Advertisement
Video content above is prompted by the following:
- What are future directions for CAR T-cell therapy in r/r B-Cell ALL?
- What unmet needs still exist in the treatment paradigm of r/r B-cell ALL?
- Can each of you share any key takeaways or additional data updates that you would like to highlight surrounding r/r B-cell ALL presented at EHA 2024? (if time permits)
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5